Literature DB >> 11093455

Twenty-four hour intraesophageal pH monitoring in children and adolescents with scleroderma and mixed connective tissue disease.

P Weber1, G Ganser, M Frosch, J Roth, G Hülskamp, K P Zimmer.   

Abstract

OBJECTIVE: To investigate esophageal dysmotility and gastroesophageal reflux, which are important, but often occult features of gastrointestinal (GI) involvement in children and adolescents with mixed connective tissue disease (MCTD) and scleroderma.
METHODS: We carried out intraesophageal 24 h pH monitoring of 14 patients with scleroderma and MCTD.
RESULTS: We observed an elevated reflux index in 64% of the patients. An increased number of reflux events was found in 85%. Reflux events > 5 min were noted in 50% of the patients, which is indicative of possible development of esophagitis. Only 3 patients presented clinical symptoms. Four of 5 patients with localized scleroderma revealed a pathological reflux index. We found no relationship between gastroesophageal reflux, age of patients, duration of disease, and Raynaud's phenomenon.
CONCLUSION: GI involvement in children with scleroderma or MCTD is more frequent than clinical symptoms indicate. An active diagnostic investigation for GI dysmotility and gastroesophageal reflux is necessary to detect these complications.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11093455

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  10 in total

Review 1.  Juvenile systemic scleroderma.

Authors:  A Martini
Journal:  Curr Rheumatol Rep       Date:  2001-10       Impact factor: 4.592

Review 2.  Systemic manifestations in localized scleroderma.

Authors:  Francesco Zulian
Journal:  Curr Rheumatol Rep       Date:  2004-12       Impact factor: 4.592

3.  [Gastrointestinal involvement in systemic sclerosis. An underestimated complication].

Authors:  P Saar; T Schmeiser; I H Tarner; U Müller-Ladner
Journal:  Hautarzt       Date:  2007-10       Impact factor: 0.751

4.  Profile of gastrointestinal involvement in patients with systemic sclerosis.

Authors:  T Schmeiser; P Saar; D Jin; M Noethe; A Müller; N Soydan; P D Hardt; C Jaeger; O Distler; E Roeb; R G Bretzel; U Müller-Ladner
Journal:  Rheumatol Int       Date:  2011-07-19       Impact factor: 2.631

Review 5.  Systemic and localized scleroderma in children: current and future treatment options.

Authors:  Margalit E Rosenkranz; Lucila M A Agle; Petros Efthimiou; Thomas J A Lehman
Journal:  Paediatr Drugs       Date:  2006       Impact factor: 3.022

6.  Esophageal disease in progressive systemic sclerosis.

Authors:  Ellen C Ebert
Journal:  Curr Treat Options Gastroenterol       Date:  2008-02

Review 7.  Development of minimum standards of care for juvenile localized scleroderma.

Authors:  Tamás Constantin; Ivan Foeldvari; Clare E Pain; Annamária Pálinkás; Peter Höger; Monika Moll; Dana Nemkova; Lisa Weibel; Melinda Laczkovszki; Philip Clements; Kathryn S Torok
Journal:  Eur J Pediatr       Date:  2018-05-04       Impact factor: 3.183

Review 8.  Pediatric scleroderma: systemic or localized forms.

Authors:  Kathryn S Torok
Journal:  Pediatr Clin North Am       Date:  2012-04-06       Impact factor: 3.278

Review 9.  Evaluation and management of esophageal manifestations in systemic sclerosis.

Authors:  Konstantinos Denaxas; Spyros D Ladas; George P Karamanolis
Journal:  Ann Gastroenterol       Date:  2018-01-18

Review 10.  Esophageal manifestation in patients with scleroderma.

Authors:  Theodoros A Voulgaris; Georgios P Karamanolis
Journal:  World J Clin Cases       Date:  2021-07-16       Impact factor: 1.337

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.